Unique ID issued by UMIN | UMIN000011541 |
---|---|
Receipt number | R000013498 |
Scientific Title | Multi-institutional Prospective Registry in Pulmonary Hypertension associated with Respiratory Disease |
Date of disclosure of the study information | 2013/09/01 |
Last modified on | 2022/03/01 08:40:29 |
Multi-institutional Prospective Registry
in Pulmonary Hypertension associated
with Respiratory Disease
Japan Respiratory PH study
Multi-institutional Prospective Registry
in Pulmonary Hypertension associated
with Respiratory Disease
Japan Respiratory PH study
Japan |
Pulmonary Hypertension Associated
with Respiratory Disease
Pneumology |
Others
NO
First prospective registry in pulmonary hypertension (PH) associated with respiratory disease including borderline PH confirmed by right heart catheterization in Japan. Prevalence of pulmonary arterial hypertension (PAH) specific therapy for PH associated with respiratory disease, course, survival and prognostic factors, efficacy and safety of PAH specific drugs are investigated.
Safety,Efficacy
Others
Others
Not applicable
Lung transplantation
Worsening of NHYA,
Addition of PAH specific drugs,
Hospitalization due to PH
Prevalence of progression from borderline PH
Liver dysfunction
Edema
Adverse effects of drugs
Pregnancy
Hospitalization due to infection and respiratory failure
Mechanical ventilation
Observational
18 | years-old | <= |
Not applicable |
Male and Female
Patients >=18 years old with PH including borderline PH (mean pulmonary arterial pressure 20-25mmHg) associated with respiratory disease by right heart catheterization
Patients who refused this study
Under 18 years old
400
1st name | Nobuhiro |
Middle name | |
Last name | Tanabe |
Graduate School of Medicine, Chiba University
Department of Advanced Medicine in Pulmonary Hypertension
260-8670
1-8-1 Inohana, Chuou-ku, Chiba 263-0043
043-222-7171
ntanabe@faculty.chiba-u.jp
1st name | Nobuhiro |
Middle name | |
Last name | Tanabe |
Graduate School of Medicine, Chiba University
Department of Respirology
260-8670
1-8-1 Inohana, Chuou-ku, Chiba 263-0043
043-222-7171
ntanabe@faculty.chiba-u.jp
Steering Committee for Multi-institutional Prospective Registry in Pulmonary Hypertension associated
with Respiratory Disease
NPO Japan PH Registry
Self funding
Japan
Department of Healthcare Quality Assessment, Graduate School of Medicine, University of Tokyo, The University of Tokyo
Graduate School of Medicine, Chiba University
1-8-1 Inohana, Chuou-ku, Chiba
043-222-7171
igaku-rinri@office.chiba-u.jp
NO
北海道大学病院第一内科(北海道)、JA北海道厚生連帯広厚生病院(北海道)、千葉大学大学院医学研究院呼吸器内科学(千葉県)、東邦大学医療センター佐倉病院(千葉県)、東京大学循環器内科(東京都)、順天堂大学呼吸器内科(東京都)、JR東京総合病院呼吸器内科 (東京都)、東海大学八王子医療センタ(東京都)、JCHO東京新宿病院(東京都)、慶應義塾大学医学部(東京都)、杏林大学循環器内科(東京都)、国立病院機構東京病院(東京都)、国際医療福祉大学三田病院(東京都)、神奈川県立呼吸器循環器病センター(神奈川)、東海大学医学部付属病院(神奈川県)、信州大学第一内科(長野県)、長野赤十字病院(長野県)、金沢市立病院(石川県)、公立陶生病院呼吸器・アレルギー内科(愛知県)、京都大学大学院医学研究科呼吸器内科学(京都府)、奈良県立医科大学第ニ内科(奈良県)、国立循環器病研究センター(大阪府)、国立病院機構近畿中央胸部疾患センター(大阪府)、大阪市立総合医療センター(大阪府)近畿大学医学部呼吸器・アレルギー内科(大阪府)、神戸大学医学部付属病院(兵庫県)、国立病院機構岡山医療センター(岡山県)、福岡大学医学部呼吸器内科(福岡県)
2013 | Year | 09 | Month | 01 | Day |
https://www.jstage.jst.go.jp/article/circj/85/4/85_CJ-20-0939/_article
Partially published
https://www.jstage.jst.go.jp/article/circj/85/4/85_CJ-20-0939/_article
281
281 patients with R-PH were included in this study. 43% had mild ventilatory impairment (MVI), 52% had a severe form of PH. 68% received PAH-targeted therapies. In MVI, those treated initially had better survival than patients not treated initially (3-year survival 70.6% vs. 34.2%; P=0.01), and no significant difference was obsereved in severe ventilatory impairment (49.6% vs. 32.1%; P=0.38). Responders to PAH-targeted therapy were more prevalent in the group with MVI.
2021 | Year | 08 | Month | 30 | Day |
2021 | Year | 02 | Month | 02 | Day |
Enrolling by invitation
2013 | Year | 05 | Month | 31 | Day |
2013 | Year | 05 | Month | 31 | Day |
2013 | Year | 09 | Month | 01 | Day |
2025 | Year | 12 | Month | 31 | Day |
Prospective descriptions of new and additional treatment for respiratory PH.
Analysis of effects of PAH specific drugs in following subcategories
Subcategorical analysis
Severity of PH (mean PA 25 to 35mmHg and >=35mmHg)
Pulmonary arterial wedge pressure (=<15mmHg and >15mmHg)
Diseases
Effects of PAH specific drugs for exercise tolerance, hemodynamic parameters by right heart catheterization, and gas exchange.
Especially efficacy and safety of PDE-5 inhibitors for respiratory PH.
Clarify the characteristics of Responder for PAH therapy
2013 | Year | 08 | Month | 21 | Day |
2022 | Year | 03 | Month | 01 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000013498
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |